TA
VRTX icon

TKG Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

TKG Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,247
Closed -$548K – 94
2024
Q4 		$548K Buy
1,247
+623
+100% +$289K 0.25% 58
2024
Q3 		$290K Sell
624
-16
-3% -$7.69K 0.14% 83
2024
Q2 		$300K Sell
640
-119
-16% -$51.7K 0.16% 79
2024
Q1 		$317K Sell
759
-14
-2% -$5.92K 0.18% 81
2023
Q4 		$315K Sell
773
-134
-15% -$49.5K 0.19% 73
2023
Q3 		$315K Buy
907
+5
+0.6% +$1.75K 0.21% 75
2023
Q2 		$317K Sell
902
-451
-33% -$152K 0.21% 73
2023
Q1 		$426K Buy
1,353
+1
+0.1% +$300 0.27% 59
2022
Q4 		$390K Buy
+1,352
New +$412K 0.26% 64

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TKG Advisors's VRTX Position: Q1 2025 in Review

TKG Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,247 shares — an estimated $548K sold.

TKG Advisors first reported a position in VRTX in Q4 2022 and held it in 9 quarters. The position peaked at $548K in Q4 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • TKG Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • TKG Advisors sold 1,247 Vertex Pharmaceuticals shares in Q1 2025, an estimated $548K.
  • TKG Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • TKG Advisors's Vertex Pharmaceuticals position peaked at $548K in Q4 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on TKG Advisors's 13F filing for Q1 2025, filed 28 Apr 2025.